CRP and melanoma: In non‐small‐cell lung carcinoma (NSCLC), melanoma, urothelial carcinoma and RCC, a meta‐analysis of 13 cohorts treated with ICIs revealed that high baseline CRP levels were associated with low overall survival (OS) and progression‐free survival (PFS) in NSCLC, melanoma, urothelial carcinoma and RCC.18